> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Boxed Warning for Veozah Liver Injury
- URL: https://www.fdaweb.com/boxed-warning-for-veozah-liver-injury/
- Published: 2025-01-02T12:00:00.000Z
- Updated: 2026-09-14T14:49:35.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158374

FDA says it has added a Boxed Warning to labeling for Astellas’ Veozah (fezolinetant) to highlight the known risk of rare but serious liver injury associated with using the menopause medication. A drug safety [notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due?ref=fdaweb.com) updates the agency’s 9/12/2024 drug safety communication warning that Veozah, used to treat hot flashes due to menopause, can cause rare but serious liver injury. That communication recommends stopping the medicine if there are signs and symptoms suggesting liver injury.